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Summary
Background.— Haemodialysis patients often have impaired vascular function that can con-
tribute to mortality. Endothelial-dependent and -independent vascular function can be assessed
using the brachial artery reactivity (BAR) technique that measures ﬂow-mediated dilatation
(FMD) and the response to glyceryl trinitrate (GTN), respectively.
Aims.— The aim of this pilot study was to determine whether BAR measurements in haemodial-
ysis patients were associated with mortality.
Methods.— Brachial artery responses to FMD and administration of GTN were assessed in
consecutive haemodialysis patients. Patients were then followed up to 18 months after BAR
measurements.
Results.— Seventeen patients were included in the study. After 18 months of follow-up, patients
were divided into two groups: survived (n = 12) and deceased (n = 5). Patients who survived had
a signiﬁcantly greater median percentage vasodilatation to GTN than those who died (19.1% vs
8.8%; P = 0.04); and a signiﬁcantly greater median area under the diameter change—time curve
(318 vs 146mm/sQ2; P = 0.03). However, there were no signiﬁcant differences between survivors
Abbreviations: AUC, Area Under the Curve; BAR, Brachial Artery Reactivity; CAD, Coronary Artery Disease; CRP, C-Reactive Protein;
VD, Cardiovascular Disease; ESKD, End-Stage Kidney Disease; FMD, Flow-Mediated Dilatation; GTN, Glyceryl Trinitrate; HDL, High-Density
ipoprotein; IMT, Intima-Media Thickness; LDL, Low-Density Lipoprotein; MI, Myocardial Infarction; NATA, National Association of Testing
uthorities; NO, Nitric Oxide; RH, Reactive Hyperaemia.
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and deceased in median percentage vasodilation to FMD (6.0% vs 4.3%; P = 0.21), time to peak
dilation (45 vs 40 s; P = 0.66) or area under the diameter change—time curve (35.5 vs 20 mm/s;
P = 0.29).
Conclusion.— In this pilot study in a small group of haemodialysis patients, endothelial-
independent vasodilatory response to GTN was associated with mortality and was of better
prognostic value than the endothelial-dependent response to FMD. This ﬁnding needs to be
investigated in a larger cohort.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Justiﬁcation.— Les patients hémodialysés ont fréquemment une dysfonction vasculaire qui peut
être un facteur de surmortalité. La fonction vasculaire endothélium-dépendante et indépen-
dante peut être évaluée par la réactivité de l’artère brachiale (BAR), technique qui mesure la
dilatation ﬂux-dépendant (FMD) et la réponse au glycéryl trinitrate (GTN), respectivement.
Objectifs.— L’objectif de cette étude pilote était de déterminer si la réactivité de l’artère
brachiale chez les patients hémodialysés est associée à une surmortalité.
Méthode.— La réponse de l’artère brachiale à la dilatation ﬂux-dépendante et l’administration
du glycéryl trinitrate ont été évaluées chez des patients hémodialysés consécutifs. Ces patients
ont été suivis pendant 18mois après détermination des paramètres de réactivité de l’artère
brachiale.
Résultats.— Dix-sept patients ont été inclus dans l’étude pilote. Après un suivi de 18mois,
les patients ont été divisés en deux groupes : survivants (n = 12) et décédés (n = 5). Les patients
survivants avaient de fac¸on signiﬁcative une vasodilatation accrue, en réponse au glycéryl trini-
trate, comparativement aux patients décédés (19,1 vs 8,8 % ; p = 0,04) et une médiane de surface
sous la courbe diamètre/temps plus élevée (318 vs 146mm/s : p = 0,03). Cependant, il n’y avait
pas de différence signiﬁcative entre les patients survivants et décédés en ce qui concerne la
valeur médiane de la vasodilatation ﬂux-dépendante, exprimée en pourcentage (6,0 % vs 4,3 % ;
p = 0,21), le délai d’apparition de la dilatation maximum (45 vs 40 s ; p = 0,66) ou la surface sous
la courbe variation de diamètre par rapport au temps (35,5 vs 20mm/s ; p = 0,29).
Conclusion.— Dans cette étude pilote ayant inclus un petit groupe de patients hémodialysés, la
vasodilatation endothélium-indépendante en réponse au glycéryl trinitrate est associée à une
surmortalité, et à une meilleure valeur prédictive pronostique que la réponse endothélium-
dépendante de la dilatation ﬂux-dépendante. Cette observation nécessite une conﬁrmation
dans des études prospectives de cohortes.
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Background
The ability of arteries to dilate in response to stimuli is
an important indicator of underlying vascular disease [1,2].
Major modulators of vascular dilatation are arterial compli-
ance and endothelial and smooth muscle function. Factors
controlling vasodilation include the release of vasoac-
tive compounds from the endothelium and the stiffness
of the arteries. In healthy individuals, one of the major
mechanisms responsible for vasodilation is the hyperaemic-
stimulated release of NO from the endothelium, resulting in
vascular smooth muscle relaxation [3].
The most common non-invasive technique to assess the
vasodilatory capacity is the BAR procedure. This tech-
nique uses high-resolution ultrasound to measure changes
in brachial artery diameter to endogenous production of
vasodilatory compounds via FMD. Following FMD, assess-
ment of endothelial-independent vasodilation is performed
by administering GTN to generate NO independently from
the endothelium. This reﬂects vascular smooth muscle func-
tion and arterial compliance.
Despite a number of studies investigating the prognostic
value of FMD [1,2,4—7], only one has included haemodialysis
H
G
us droits réservés.
atients [8]. In this study, data from the dialysis patients
ere pooled with those of other individuals at risk of cardio-
ascular events or divided into those with or without CAD.
iven the knowledge that some studies [9,10], but not all
11] have reported that dialysis patients have impaired BAR,
e thought it important to assess the prognostic value of BAR
ata in haemodialysis patients. Furthermore, most studies
ave investigated ability of BAR measures to be associated
ith cardiovascular events rather than mortality [1,2,4—8].
herefore, the long-term goal is to investigate the whether
AR measures are associated with all-cause mortality in
aemodialysis patients. The aim of this pilot study is to
ollect data to assist in the design of this larger study and
o provide data for future meta-analyses on this topic.
ethods
tudy populationaemodialysis patients were recruited from the Launceston
eneral Hospital and the North-West Tasmanian dialysis
nit. Consecutive patients attending the dialysis units over
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2-week period who agreed to participate in the study
ere recruited. All patients were receiving haemodialysis
hree times a week using a polysulphane membrane dialyser
ith each session lasting 3 to 4 hours.
Patient records were assessed for risk factors associated
ith CVD and those with an arteriovenous ﬁstula in both
ight and left arms were excluded. None of the patients were
mokers (deﬁned as smoking≥ one cigarette per day for > 1
ear within the last 5 years). Full lipid proﬁles (total, LDL
nd HDL cholesterol and triglycerides) were conducted on
ll patients in the week prior to testing following a 12-hour
ast.
Each patient provided written informed consent. The
tatewide Tasmanian Human Scientiﬁc Ethics Committee
pproved the study and it was carried out in accordance
ith the declaration of Helsinki (2000) of the World Medical
ssociation.
rachial artery reactivity and carotid artery
ntima media thickness
ll testing procedures have been explained in a previous
tudy [12]. The repeatability of the BAR protocol and the
easurement of IMT was determined in a separate study
here six healthy subjects had their IMT measured and were
ssessed for their vasodilatory response to RH and GTN on
wo occasions separated by 24 hours. The mean absolute dif-
erences between the 2 days were 1.7% for RH, 2.1% for GTN
nd 1.2% for IMT.
iochemical analyses
easurements were carried out in the NATA-accredited
athology laboratory at the Launceston General Hospi-
al. Total cholesterol, HDL cholesterol and triglycerides
ere measured with an automated analyser (Olym-
us Au600 Clinical Chemistry Analyser, Mishima Olym-
us Co. Ltd, Japan). LDL cholesterol was calculated
sing the Friedewald equation LDL = total cholesterol—HDL
holesterol—(triglycerides/2.2). CRP was determined by
easuring the absorbance of insoluble aggregates formed
hen antihuman CRP antibodies were added to patient sam-
les.
ollow-up
ighteen months after the baseline measurements, research
taff in the dialysis units conﬁrmed deaths via medical
ecords. At this time, the remaining patients were still
ttending the units, allowing conﬁrmation of survival.
ata analysis
s this was a pilot study, a sample size calculation was
ot performed. To determine AUC, individual responses to
H and GTN were plotted using PRISM (v2, GraphPad Soft-
are, San Diego, CA, USA), converted to TIFF ﬁles, and AUC
as determined using Analytical Imaging Station software
Imaging Research, St Catherine’s, Canada) as previously
escribed [12].
Patients were followed for 18 months and then divided
nto two groups: survived and deceased. A two-sample
o
t
t
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ilcoxon rank-sum (Mann-Whitney) test was used to com-
are variables between these groups. These analyses
howed that the response of the brachial artery to GTN
as different between groups. This prompted the use of
ox proportional multivariable regression to assess the inde-
endence of GTN or RH to dilate the brachial artery and
nvestigate the association with mortality. Furthermore, a
ox proportional hazards model was used to compare GTN
ilation with variables selected based on previous evidence
f their association with mortality in haemodialysis patients:
ge, CRP, carotid IMT and supine pulse pressure [13—15].
PSS version 11.0.0 (Chicago, IL, USA) was used for all
tatistical methods. A P value of < 0.05 was considered sta-
istically signiﬁcant.
esults
n total, 17 patients (13 male, four female) were included
n this study. Of these, 16 patients had previously been
iagnosed with hypertension, ﬁve had type 2 diabetes and
1 were diagnosed with atherosclerosis (either angiographi-
ally determined or with a documented vascular incident).
ive of the 17 patients died within the 18-month follow-up
eriod due to withdrawal from dialysis (n = 3) and MI (n = 2).
here were a total of 16 cardiovascular events (including the
wo deaths from MI), and 13 of these occurred in individuals
ho had survived 18 months.
Table 1 shows clinical and biochemical characteristics of
he patients. There were no signiﬁcant differences in any
f the biochemical parameters between the patients who
ied within 18 months of the BAR measures and those who
urvived.
BAR data are reported in Table 2 and displayed in Fig. 1.
he response of the artery was quantiﬁed in four ways:
bsolute change, relative change, time to peak response
nd change in diameter over time (represented as AUC).
ilation following GTN was signiﬁcantly lower in patients
hat died within 18 months by absolute change, relative
hange and AUC (all P < 0.05; Table 2). FMD measures and the
atio of RH to GTN were not signiﬁcantly different between
roups.
The low number of deaths limited multivariable analysis.
owever, Cox proportional hazards analysis showed that the
ssociation between dilation following GTN and death was
ndependent of dilation following RH ( = 1.12, P = 0.04), but
as not independent of known risk factors (age, CRP, carotid
MT and supine pulse pressure) (P > 0.05).
iscussion
on-invasive ultrasound assessment of BAR is being widely
sed to study endothelial and smooth muscle function.
he predictive value of data from this procedure has been
ssessed in various patient groups at risk of CVD [1,2,4—8].
owever, this is the ﬁrst study to determine its prognostic
bility in solely haemodialysis patients. The major ﬁndings
f this pilot study are that, in these haemodialysis patients,
he endothelial-independent response of the brachial artery
o GTN was associated with 18-month mortality, and this
ssociation was greater than dilation due to RH. This was a
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Table 1 Clinical and biochemical characteristics of the haemodialysis patients.
All patients Survived > 18months Died within 18months P
(n = 17) (n = 12) (n = 5)
Age (years) 60 (23—78) 60 (23—76) 68 (52—78) 0.09
Male/female 13/4 10/2 3/2 0.90
Time on dialysis (months) 25.5 (1.5—60.5) 24.8 (1.5—60.5) 34.0 (7.0—41.0) 1.00
Standing SBP (mmHg) 130 (105—160) 130 (105—160) 132 (112—150) 0.49
Standing DBP (mmHg) 75 (54—100) 78 (60—100) 72 (54—80) 0.31
Standing pulse pressure (mmHg) 52 (15—85) 50 (15—85) 62 (47—78) 0.25
Supine SBP (mmHg) 142 (108—172) 136 (108—172) 142 (138—170) 0.43
Supine DBP (mmHg) 80 (60—100) 80 (60—100) 80 (76—98) 0.75
Supine pulse pressure (mmHg) 58 (30—110) 54 (30—110) 62 (56—80) 0.31
Total cholesterol (mmol/L) 4.5 (2.8—6.4) 4.5 (3.0—6.4) 4.6 (2.8—5.3) 0.96
LDL cholesterol (mmol/L) 2.1 (1.3—4.0) 2.1 (1.3—4.0) 2.6 (1.6—3.1) 1.00
HDL cholesterol (mmol/L) 1.1 (0.7—2.1) 1.1 (0.7—2.1) 1.2 (0.7—1.9) 0.49
LDL/HDL ratio 2.1 (1.2—4.3) 2.2 (1.2—4.3) 2.0 (1.6—2.4) 0.67
Triglycerides (mmol/L) 1.7 (0.6—4.9) 1.7 (0.8—4.9) 1.4 (0.6—1.8) 0.22
CRP (mg/L) 13 (1—155) 14 (1—155) 8 (2—136) 0.29
Data are median (range) or n/n. CRP: C-reactive protein; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density
lipoprotein; SBP: systolic blood pressure.
t
i
thypothesis-generating exercise and these data will be use-
ful in the design of a larger trial and for meta-analytical
purposes.Most studies have reported that responses of the brachial
artery to RH, but not GTN, are lower in patients with subse-
quent cardiac events [1,2,4—8]. A potential explanation for
h
w
b
Table 2 Response to reactive hyperaemia and glyceryl trinitr
All patients
(n = 17)
IMT (mm) 0.9 (0.5—1.9)
FMD measures
Baseline brachial artery diameter
before RH (mm)
4.4 (3.4—5.7)
Maximal brachial artery distension
during RH (mm)
0.2 (0.0—0.7)
Maximal brachial artery distension
during RH (%)
5.6 (0.0—19.4)
Time to peak response during RH (s) 40 (20—140)
AUC during RH (mm·s) 32 (0—80)
GTN measures
Baseline brachial artery diameter
before GTN (mm)
4.4 (3.4—5.6)
Maximal brachial artery distension
after GTN (mm)
0.7 (0.3—1.4)
Maximal brachial artery distension
after GTN (%)
13.8 (6.4—34.2)
Time to peak response after GTN (s) 310 (180—620)
AUC following GTN (mm·s) 210 (20—513)
Ratio of % RH/% GTN (%) 40 (0—100)
Data are median (range). AUC: area under the curve; FMD: ﬂow-m
thickness; RH: reactive hyperaemia.he discrepancy between these previous studies and our ﬁnd-
ngs may be related to the patients studied, as only one of
hese included any haemodialysis patients [8]. In that study,
aemodialysis patients were either grouped with patients
ith CAD or divided into those with or without CAD. It has
een postulated that uraemia associated with ESKD results
ate (GTN).
Survived > 18months Died within 18 months P
(n = 12) (n = 5)
0.9 (0.5—1.9) 1.0 (0.5—1.2) 0.71
4.4 (3.6—5.7) 4.7 (3.4—4.8) 0.67
0.3 (0.0—0.7) 0.2 (0.1—0.3) 0.19
6.0 (0.0—19.4) 4.3 (2.1—8.8) 0.21
45 (20—130) 40 (20—140) 0.66
35.5 (0—80) 20 (0—38) 0.29
4.5 (3.6—5.6) 4.4 (3.4—4.7) 0.43
0.9 (0.4—1.4) 0.3 (0.3—0.8) 0.02
19.1 (7.8—34.2) 8.8 (6.4—18.2) 0.04
295 (180—480) 400 (280—620) 0.12
318 (20—513) 146 (105—342) 0.03
30 (0—75) 67 (11—100) 0.29
ediated dilatation; GTN: glyceryl trinitrate; IMT: intima-media
522
Figure 1. Changes in brachial artery diameter during FMD (A) and
following GTN administration (B). All values are mean± SEM. In Fig-
ure 1A, time 0 represents the ﬁrst recording, which was taken at
20 s, following 5min of forearm occlusion. In Figure 1B, the ﬁrst
recording was taken 2min after administration of sublingual GTN.
The horizontal broken lines represent the baseline measurements
above which AUC was calculated. FMD: ﬂow-mediated dilation;
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prospective study. Circulation 2002;105:1567—72.TN: glyceryl trinitrate; SEM: standard error of the mean; AUC:
rea under the curve.
n an atherosclerotic environment that may be different to
hat of CAD patients [11].
A potential mechanism to explain the diminished vasodi-
ation due to GTN is increased arterial stiffness, impairing
he ability of GTN-derived NO to cause vasomotion; whereas
uring RH, other known endothelial-derived vasodilators
e.g. prostaglandins and cytochrome P450 metabolites) may
ssist NO in overcoming the stiff artery [16]. Indeed, it has
een shown that haemodialysis patients have increased aor-
ic stiffness compared to matched controls [17], and this is
n independent risk factor for cardiovascular mortality [18].
urthermore, it has been demonstrated that, in individu-
ls with CAD, the role of NO may be diminished compared
o other vasodilators [16]. Recently, hydrogen peroxide has
een shown to cause vasodilation by hyperpolarizing smooth
uscle [19], and hydroxyl radicals have been implicated ashe mechanism responsible for acetylcholine dilation [20].
owever, arterial stiffness predominantly affects large elas-
ic arteries, such as the aorta, rather than the muscularB.S. Dalton et al.
rachial artery assessed in this study. Therefore, an assess-
ent of arterial stiffness would be a suggestion for future
tudies.
One of the major differences between this study and pre-
ious investigations reporting the prognostic value of BAR
ata was our decision to look at all-cause mortality rather
han CVD mortality or CVD events. This decision was based
n the knowledge that vascular dysfunction affects more
han just cardiovascular endpoints and is known to con-
ribute signiﬁcantly to renal dysfunction [21]. Indeed, three
f the individuals died from complications of ESKD.
Clearly, the small number of patients and their rate of
ortality over the 18 months is a limitation of this study.
owever, we were so impressed with the magnitude of dif-
erence in the GTN response between the survivors and
hose who died that we feel that this is worth reporting.
n addition, recent evidence suggesting the importance of
asodilatory mechanisms other than NO (e.g. those regu-
ated by reactive oxygen species), supports our ﬁndings and,
e believe, adds to the importance of our data. Certainly,
he prognostic usefulness of brachial artery responses to
TN in haemodialysis patients warrants investigation in a
arger cohort.
onclusions
n a small group of haemodialysis patients, GTN did not cause
igniﬁcant brachial artery dilation and this was associated
ith mortality. Conversely, the response to RH was not sig-
iﬁcantly different in patients who had survived or died after
8 months. These ﬁndings imply that these haemodialysis
atients had a level of arterial stiffness that was not signif-
cantly dilated by GTN. During the RH support from other
ow-derived vasoactive mechanisms may assist in vasodila-
ing the artery. However, these ﬁndings should only be
iewed as hypothesis generating and need to be investigated
n a larger sample of haemodialysis patients.
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